达可醇通过激活PPARα通路来缓解心力衰竭与保存的射出分数
Jie Zhou1, Bei Wang2, Mengyao Wang1
1Key Laboratory of Metabolism and Regulation for Major Diseases of Anhui Higher Education Institutes, College of Food and Biological Engineering, Hefei University of Technology, Hefei, China.
Heliyon
|October 17, 2024
概括
达可醇 (DAU) 在小鼠中有效地减轻心力衰竭与保存的喷射分数 (HFpEF). 这种天然化合物通过调节关键细胞通路来减少炎症和氧化应激,为HFpEF提供了潜在的新治疗途径.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 保持排气分数 (HFpEF) 的心力衰竭是一个日益严重的健康问题,其特点是保持左心室排气分数 (LVEF),腹功能障碍和全身炎症.
- 达可醇 (DAU) 是β-固醇的天然糖化物,具有已知的抗炎和抗氧化特性.
- 在HFpEF中DAU的治疗潜力仍然未被探索.
研究的目的:
- 为了研究达可醇 (DAU) 减轻HFpEF的疗效.
- 阐明DAU在临床前HFpEF模型中发挥其作用的潜在分子机制.
主要方法:
- 在C57BL/6J雄性小鼠中,使用N-nitro-l-arginine甲基 (L-NAME) 和高脂肪饮食 (HFD) 诱导HFpEF.
- 小鼠通过口腔输液接受了达可醇 (DAU) 治疗,持续了10周.
- 分析了包括PPARα和NF-κB酸化在内的关键分子通路,以评估氧化应激和炎症.
主要成果:
- 在小鼠模型中,DAU治疗显著改善了HFpEF症状.
- 服用DAU有效降低了氧化应激和炎症反应.
- 从机制上讲,DAU调节了PPARα活性,并抑制了NF-κB酸化.
结论:
- 达可醇 (DAU) 在减轻HFpEF方面显示出显著的治疗潜力.
- DAU的机制涉及通过PPARα和NF-κB通路减少氧化应激和炎症.
- 这项研究确定了达可醇作为未来HFpEF治疗开发的有希望的天然产品.
相关概念视频
01:29Heart Failure II: Pathophysiology
3
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
3
01:22Heart Failure Drugs: Diuretics
346
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
346
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:22Heart Failure Drugs: β-Blockers
320
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320
01:30Cardiomyopathy II: Dilated Cardiomyopathy
1
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
1